DE3852374D1 - Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen. - Google Patents

Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen.

Info

Publication number
DE3852374D1
DE3852374D1 DE3852374T DE3852374T DE3852374D1 DE 3852374 D1 DE3852374 D1 DE 3852374D1 DE 3852374 T DE3852374 T DE 3852374T DE 3852374 T DE3852374 T DE 3852374T DE 3852374 D1 DE3852374 D1 DE 3852374D1
Authority
DE
Germany
Prior art keywords
icam
treatment
functional derivatives
specific inflammation
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3852374T
Other languages
English (en)
Other versions
DE3852374T2 (de
Inventor
Donald Carroll Anderson
Robert Rothlein
Clinton Wayne Smith
Randall Wilbur Barton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BOEHRINGER INGELHEIM PHARMACEUTICALS Inc RIDGEFIELD CONN US
Baylor College of Medicine
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
BOEHRINGER INGELHEIM PHARMACEUTICALS Inc RIDGEFIELD CONN US
Baylor College of Medicine
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BOEHRINGER INGELHEIM PHARMACEUTICALS Inc RIDGEFIELD CONN US, Baylor College of Medicine, Boehringer Ingelheim Pharmaceuticals Inc filed Critical BOEHRINGER INGELHEIM PHARMACEUTICALS Inc RIDGEFIELD CONN US
Application granted granted Critical
Publication of DE3852374D1 publication Critical patent/DE3852374D1/de
Publication of DE3852374T2 publication Critical patent/DE3852374T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE3852374T 1987-11-02 1988-04-29 Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen. Expired - Lifetime DE3852374T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11579787A 1987-11-02 1987-11-02

Publications (2)

Publication Number Publication Date
DE3852374D1 true DE3852374D1 (de) 1995-01-19
DE3852374T2 DE3852374T2 (de) 1995-05-04

Family

ID=22363440

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3852374T Expired - Lifetime DE3852374T2 (de) 1987-11-02 1988-04-29 Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen.

Country Status (10)

Country Link
EP (1) EP0314863B1 (de)
JP (1) JP2710627B2 (de)
AT (1) ATE114972T1 (de)
AU (2) AU1550988A (de)
CA (1) CA1331132C (de)
DE (1) DE3852374T2 (de)
DK (1) DK175491B1 (de)
ES (1) ES2064327T3 (de)
GR (1) GR3015298T3 (de)
ZA (1) ZA883160B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
EP0362531B1 (de) 1988-09-01 1999-11-10 Bayer Corporation Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
AU4412889A (en) * 1988-09-28 1990-04-18 Dana-Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5235049A (en) * 1989-01-24 1993-08-10 Molecular Therapeutics, Inc. Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1
CA2008368C (en) * 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
NO900155L (no) * 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
EP0387701B1 (de) * 1989-03-09 1992-08-12 Boehringer Ingelheim Pharmaceuticals Inc. Verwendung von interzellularen Adhäsions-Molekülen und deren Bindungsliganden bei der Behandlung von Asthma
AU645016B2 (en) * 1989-06-02 1994-01-06 Johns Hopkins University School Of Medicine, The Monoclonal antibodies against leukocyte adhesion receptor beta-chain, methods of producing these antibodies and use therefore
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
EP0438312A3 (en) * 1990-01-19 1992-07-01 Merck & Co. Inc. Recombinant human anti-cd18 antibodies
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
WO1991018010A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of viral infection using intercellular adhesion molecule-1-like peptides and/or analogues thereof
WO1991018011A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of cell adhesion using intercellular adhesion molecule-1-like peptides and/or analogues thereof
DE4019024A1 (de) * 1990-06-14 1991-12-19 Bayer Ag Verwendung der efomycine a, e und g als entzuendungshemmende mittel
DK162890D0 (da) * 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
EP0468257B1 (de) * 1990-07-20 1999-09-01 Bayer Corporation Multimere Formen des menschlichen Rhinovirus-Rezeptorproteins
US5283058A (en) * 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
HU216097B (hu) * 1990-08-31 1999-04-28 Boehringer Ingelheim Pharmaceuticals Inc. Eljárás endotoxinsokk kezelésére antiadhéziós antitestek alkalmazásával
WO1992008489A1 (en) * 1990-11-08 1992-05-29 Biogen, Inc. Treatment for inflammatory bowel disease
NZ240646A (en) 1990-11-23 1994-01-26 Gen Hospital Corp Therapeutic interference between cell adhesion proteins and their
US5288854A (en) * 1990-11-28 1994-02-22 Center For Blood Research, Inc. Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
US5223396A (en) * 1991-05-03 1993-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Method for detecting organ transplant rejection
US5891841A (en) * 1991-06-11 1999-04-06 The Center For Blood Research, Inc. Methods of using intercellular adhesion molecule-3 (ICAM-3), antibodies thereto, and soluble fragments thereof
CA2120500A1 (en) * 1991-10-01 1993-04-15 Mitsuaki Isobe Preventing allograft rejection with antibodies to adhesion molecules
EP0610290B1 (de) * 1991-10-04 1999-05-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
GB9126918D0 (en) * 1991-12-19 1992-02-19 Univ London Members of specific binding pairs;methods of their making and using
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US5869262A (en) * 1992-01-27 1999-02-09 Icos Corporation Method for monitoring an inflammatory disease state by detecting circulating ICAM-R
JP3616090B2 (ja) * 1992-01-27 2005-02-02 イコス コーポレイション 細胞間接着分子関連タンパク質
US5532127A (en) * 1992-01-27 1996-07-02 Icos Corporation Assay for 1-CAM related protein expression
US5989843A (en) * 1992-01-27 1999-11-23 Icos Corporation Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein
US6818743B1 (en) 1992-01-27 2004-11-16 Icos Corporation I-CAM related protein
US6100383A (en) * 1992-01-27 2000-08-08 Icos Corporation Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions
US5525487A (en) * 1992-01-27 1996-06-11 Icos Corporation DNA encoding I-CAM related protein
US6153395A (en) * 1992-01-27 2000-11-28 Icos Corporation ICAM-related protein
ATE151642T1 (de) * 1992-02-12 1997-05-15 Biogen Inc Behandlung für entzündungserkrankung des darmes
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
WO1993017047A1 (en) 1992-02-28 1993-09-02 Board Of Regents, The University Of Texas System Compositions and methods for the treatment of thermal injury
WO1994004188A1 (en) * 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
DE4335273A1 (de) * 1993-10-15 1995-04-20 Univ Ludwigs Albert Peptide zur Tumortherapie
US5679340A (en) * 1994-03-31 1997-10-21 Diacrin, Inc. Cells with multiple altered epitopes on a surface antigen for use in transplantation
WO1995027736A1 (en) * 1994-04-12 1995-10-19 Boehringer Ingelheim Pharmaceuticals, Inc. Use of agents which block intercellular adhesion molecule/receptor interaction in the treatment of respiratory viral infection
GB9414966D0 (en) * 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
US5879712A (en) * 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
EP1682537B1 (de) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulatoren der zellulären adhäsion
ES2614080T3 (es) 2005-05-17 2017-05-29 Sarcode Bioscience Inc. Composiciones y métodos para el tratamiento de trastornos oculares
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
EP3797775A1 (de) 2007-10-19 2021-03-31 Novartis AG Zusammensetzungen und verfahren zur behandlung von diabetischer retinopathie
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
CN104797574B (zh) 2012-07-25 2019-11-22 原生质生物科学股份有限公司 Lfa-1抑制剂及其多晶型物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3854536T2 (de) * 1987-05-04 1996-03-07 Dana Farber Cancer Inst Inc Interzellulare Adhäsions-Moleküle und deren Bindungsliganden.

Also Published As

Publication number Publication date
ES2064327T3 (es) 1995-02-01
JPH01135724A (ja) 1989-05-29
ZA883160B (en) 1990-02-28
EP0314863A3 (en) 1990-04-04
DE3852374T2 (de) 1995-05-04
GR3015298T3 (en) 1995-06-30
AU1550988A (en) 1989-07-27
AU2633388A (en) 1989-07-27
AU622120B2 (en) 1992-04-02
DK239388A (da) 1989-05-03
DK175491B1 (da) 2004-11-08
CA1331132C (en) 1994-08-02
EP0314863B1 (de) 1994-12-07
JP2710627B2 (ja) 1998-02-10
DK239388D0 (da) 1988-05-03
ATE114972T1 (de) 1994-12-15
EP0314863A2 (de) 1989-05-10

Similar Documents

Publication Publication Date Title
DE3852374T2 (de) Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen.
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
ES499887A0 (es) Procedimiento e instalacion para el tratamiento de residuos agricolas liquidos
DE3687069D1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
ATE76294T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DE3878627T2 (de) Zusammensetzung zur oberflaechenbehandlung von kautschuk.
ATE95064T1 (de) Verwendung von angiotensin-converting-enzyminhibitoren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit.
ATE58900T1 (de) Diaryldiazolylmethane.
DE3680507D1 (de) Verwendung von oxirancarbonsaeuren zur behandlung der hyperlipaemie.
ATE142499T1 (de) Verwendung von kreatinphosphat oder phosphoenolbrenztraubensäure zur behandlung von tumoren
BE891629A (fr) Promoteur de coagulation du sang et procede l'utilisant
DE68907386T2 (de) Verwendung von Phytinsäure oder deren Salzen zur Verhinderung oder Behandlung von Lebererkrankungen.
ES2070134T3 (es) Inhibidores de lisil oxidasa.
ES495696A0 (es) Procedimiento e instalacion para el tratamiento de gases
DE3686688T2 (de) Verwendung von sulfanilamido quinoxalinen zur behandlung von neoplastischen krankheiten.
DE59101581D1 (de) Verwendung von efeu zur topischen behandlung der psoriasis.
DE69635131D1 (de) Verwendung von beta-interferon zur behandlung der restenose
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
AR230845A1 (es) Procedimiento para el tratamiento de sustratos de acero o de acero galvanizado
SE422473B (sv) Forfarande for behandling av fosfaterat mjukt stal eller zinkbelagt mjukt stal
DE3683330D1 (de) Verwendung von imidazolinylaminoisoindolen und verwandten verbindungen zur behandlung von hyperglykaemie.
ATE209910T1 (de) Verwendung von 6,7-substituierter 2- aminotetraline zur behandlung von zytokin- vermittleten entzündungszuständen
ATE15480T1 (de) Verfahren und faulbehaelter zur anaeroben behandlung von abwasser.
DD137699A1 (de) Verfahren zur desodorierung und nitrifikation stickstoffhaltiger abwaesser
ATE33936T1 (de) Apparat zur aeusseren behandlung von koerperteilen mit akustischen wellen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition